4A3356).
Introduction
Kinins are peptide hormones of nine or 10 amino acid residues, which are released by the enzymic action of kallikreins on their precursor proteins, kininogens (Muller-Esterl, 1993) . Kinins express their biological effects by activating specific kinin receptors situated on the plasma membrane of many cell types. At least two types of kinin receptors have been recognized (Regoli and BarabE, 1988) . The B1 receptor is induced by lipopolysaccharides (rabbit) and triggered by the bradykinin degradation product desArg9-bradykinin, and the B2 receptor is constitutively expressed on many cell types and is stimulated by bradykinin and kallidin (Lys-bradykinin). Activation of the B2 receptor induces hypotension, increases vascular Immunocytochemical localization of B2 receptor by antipeptide antibodies to the receptor confirmed these findings and demonstrated the presence of B2 receptor in the basal infoldings and luminal membranes of the tubule cells, and in smooth muscle cells of the cortical radial artery and of afferent arterioles. CO-localization of the B2 receptor with kallikrein and kininogens in connecting tubule cell and collecting duct cell layers, respectively, provides a structural basis for the hypothesized physiological functions of the kallikrein-kinin system in the kidney. (JHstochem Cytochem KEY WORDS: Rat; Kidney; Bradykinin; B2 bradykinin receptor; HOE140 antagonist; Tissue kallikrein; Kininogen; Ligand conjugate-anti-ligand approach; Binding assay; Anti-peptide antibodies; Immunocytochemistry; [ '251]-TyP-bradykinin; Autoradiography. 43: [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] 1995) permeability, provokes pain, and contracts smooth muscle cells: In the kidney, the B2 receptor has been implicated in water transport and ion exchange (Margolius, 1989) .
Kinin B2 receptor cDNAs have been cloned from rat, mouse, and human sources (Mclntyre et al., 1993; Eggerickx et al., 1992; Hess et al., 1992; McEachern et al., 1991) . Analysis of the rat B2 receptor cDNA predicts a protein sequence of 366 amino acids with a molecular mass of 41 KD, three potential N-linked glycosylation sites, and many potential phosphorylation sites (McEachern et al., 1991) . The B2 receptor is a member of the superfamily of G-proteincoupled rhodopsin-like receptors characterized by seven transmembrane regions, and stimulates the inositol triphosphate pathway via phospholipase C and/or the arachidonic pathway via phospholipase Az (Burch and Axelrod, 1987) . Northern blot analysis indicates that the B2 mRNA is present in uterus (highest level), kidney, ileum, heart, lung, testis, and brain (McEachern et al., 1991) . A similar distribution was found in human except that the kidney was the most abundant source of human B2 mRNA (Hess et al., 1992) . 
The standard one-letter code for amino acids is used.
EMCS. N-succinimidyl-6-maleimido capronic acid; EDC, l-ethyl-3-(3'-di-methylaminopropy1)carbodiimide-HCI.
B2. bradykinin B2 receptor; ED, putative extracellular domain; ID, putative intracellular domain. AS, antiserum. e Monoclonal antibodies to bradykinin (Haasemann et al., 1991) . fHOE140; ~-arginyl-arginyl-prolyl-4-hydroxyprolyl~glycyl-~-2-thienylal~y~seryl-D-1,2,3,4-tcuahydroisoquinoline-3-carboxyl-[3aS, 7aSJ-octahydroindol-2-carboxyl-arginine (Hock et al., 1991) .
g Monoclonal antibodies (Abd Alla et al.. 1993). Innis et al. (1981) were the first to report the binding of [3H]bradykinin to crude membrane preparations of mammalian cells. Their initial observations were confirmed and extended by many studies localizing bradykinin binding sites in the brain and nervous system (Lopes et al., 1993; Privitera et al., 1991; Fujiwara et al., 1989; Steranka et al., 1988; Manning and Snyder, 1983) , in lung (Mak and Barnes, 1991), in ureter, and in kidney (Bascands et al., 1989; Manning and Snyder, 1989; Tomita and Pisano, 1984) . With [3H]-bradykinin, the gross distribution of bradykinin binding sites was examined in guinea pig kidney, demonstrating that bradykinin receptors are concentrated in the outer medulla, inner medulla, and pelvic capsule (Manning and Snyder, 1989) . However, a precise mapping of the B2 receptor distribution in mammalian kidney was not given.
In these studies we investigated the occurrence and distribution of bradykinin-binding sites in rat kidney using a novel approach in which conjugates of the authentic B2 agonist bradykinin or a B2 antagonist, HOE140, with bovine serum albumin (BSA) were applied to renal tissue sections. Binding of the conjugates was probed by antibodies directed to the respective ligand. With this technique the presence of bradykinin binding sites was demonstrated in cells comprising the collecting ducts, connecting tubules, straight distal tubules, and straight portions of the proximal tubules. Application of anti-peptide antibodies directed against the various segments of the predicted rat B2 receptor sequence demonstrate that the ligand-probed bradykinin-binding sites co-localize with the antigenic B2 receptor sites.
Materials and Methods
P r e p t i o n of Conjugates and Anti-ligand Antibodies. Coupling of B2 receptor ligands, bradykinin (Sigma; St Louis, MO), or HOE140 (D-Argo-Hyp3-Thi5-~-Tic7-Oic8-bradykinin; 6. 'Czble 1) to BSA (Sigma) was performed using l-ethy1-3(3'-dimethylaminopropyl)carbodiimide-HCl (EDC) according to Goodfriend et al. (1964) , with minor modifications as described previously (Abd Alla et al., 1993; Haasemann et al., 1991) . For control, a conjugate of angiotensin I1 (Sigma) and BSA was prepared. Quantitative amino acid analysis of the HOE140-BSA conjugate using P-2-thienylalanine and 4-hydroxyproline as the reference residues revealed a molar ratio of 1.39 * 0.05 of peptide over carrier protein. This indicates that 230% of the conjugate population has two or more HOE peptides conjugated per molecule of BSA. A single conjugate preparation each of HOE140, bradykinin, and angiotensin, was used throughout this study. Poly-and monoclonal antibodies (MAbs) to the ligand conjugates were raised and their specificity established as detailed elsewhere (Abd Alla et al., 1993; Haasemann et al., 1991) . In this study we applied murine MAbs to bradykinin, MBKl to MBK3 (IgGi subtype) (Haasemann et al., 1991) , to HOE140, MHO1, and MHO2 (IgG subtype) (Abd Alla et al., 1993) . and rabbit polyclonal antiserum to HOE140 (Abd Alla et al., 1993) . The method for indirect immunodetection of functional bradykinin binding sites by the ligand-BSA conjugate is diagrammed in Figure 1 .
Characterization of Ligand Conjugates. The resultant conjugates were tested by indirect ELISA (Engvall and Perlmann, 1971) . with minor modifications (Haasemann et al., 1991) . Briefly, Maxisorb microtiter plates (Nunc; Wiesbaden, Germany) were coated with 2 pglml of the peptides or 0.5 pglml of the conjugates, followed by a serial dilution (2"; starting concentration of 20 pglml) of the respective MAb (MBK3. MHO1). and a peroxidase-conjugated secondary antibody to mouse IgG (Sigma; dilution 1:3000). The chromogenic substrate was 2,2-azino-bis(3-ethyI-2,3-dihydrobenzthiazoline-6-sulfonate) (ABTS). To further characterize the ligand conjugates, a competitive receptor-binding assay was performed following previously published procedures (Abd Alla et al.. 1993) . Briefly, membranes prepared from human foreskin fibroblasts (kindly provided by Dr. A. Roscher, Munich) were incubated for 120 min at 4'C with 2 nM (0.1 pCi) of [2,3-pr0Iyl-3,4-~H]-bradykinin, 2 mM bacitracin in 20 mM piperazine-N,N-bis(2-ethanesulfonic acid), pH 6.8, in the absence or presence of increasing concentrations (1 pM-10 pM) of the competitor. Protein-bound and free ligand were separated by filtration over Whaunan glass filters GF/C pre-coated with 0.3% (wlv) of polyethyleneimine. Filter-bound radioactivity was measured in a liquid scintillation counter in the presence of Aquasafe 300 (Zinsser; Frankfurt, Germany). Specific binding was calculated as the difference between total and nonspecific binding. Displacement studies were done in triplicate for each ligand.
Production of Anti-peptide Antibodies to the Kinin Receptor. Eight peptide segments were selected from the sequence of the rat B2 receptor (McEachetn et al., 1991) by the criteria of hydrophilicity. relative location in the receptor protein, and presence of a cysteine residue for coupling, if present ('lible 1). In this way, peptides covering seven ofthe eight predicted intra-and extracellular domains of the transmembrane-spanning receptor were synthesized using the t-BOC chemistry. The identity of the HPLCpurified peptides was routinely established by E h degradation and electro-spray mass spectrometry. After characterization, each peptide was COMlently coupled to keyhole limpet hemocyanin via bifunctional cross-linking using N-succinimidyl-6-malehido capronic acid and l-ethyl-3( 3'-dimethyl-aminopropy1)carbodiimide-HC1. The conjugates were used for generation of eight antisera (AS276 to AS283; Table 1) in rabbits according to established immunization procedures. An indirect ELISA technique with the unmodified peptides as the capture antigens (Kaufmann et al., 1993) was employed to follow the titer of the anti-peptide antisera and to establish their specificity. Crossreactivity of the anti-peptideantibodies with the rat B2 receptor was demonstrated by Western blot analysis (data not shown). Binding of Ligand Conjugates to Tissue Sections. Dewaxed and rehydrated renal tissue sections (from three rats) fixed in periodate-lysineparaformaldehyde were washed with 0.05 M Xis-HCI, pH 7.6, containing 1 mM EDTA. 1 mM EGTA, 20 pM captopril (Sigma), 0.1% (w/v) BSA (Buffer A), and incubated with various concentrations of bradykinin-BSA or HOEMO-BSA for 18 hc at 4'C. The ligand conjugate concentrations tested were 20, 10, 5, 2, 1, 0.25, 0.15, and 0.05 pglml. For comparison, various concentrations (W3, lo4, lod, and lo-' M) of uncoupled bradykinin or HOE140 were used to incubate consecutive tissue sections. After incubation the sections were washed three times for 3 min with ice-cold Buffer A, air-dried, and Fie3 with acetone for 5 min. The sections were pre-treated with absolute methanol and 1% (v/v) H202 in 0.05 M TriS-HCl buffer, pH 7.6, for 15 min each to block pseudoperoxidase activity. Bound ligand conjugates were detected by the peroxidase-anti-peroxidase method (see below) using a specific antiserum to HOE140 (AS255,1:1000), MAbs to HOE140 (MHO1, culture supernatant, 1:loO; MH02, ascites fluid, 1:5000), or MAbs to bradykinin (MBK1, MBK2, MBK3; affinity-purified MAbs; 10 pg/ml) diluted in Buffer A.
Controls were carried out (a) by omission ofthe ligand conjugate from the incubation &re.
(b) by omission of the primary antibody, or (c) by replacement of the primary antibody with an isotype-matched MAb, IgGi antibody to Rspergi//ur #&er glucose oxidase (Dako; Glosuup, Denmark); this enzyme is neither present nor inducible in mammalian tissues.
Specificity of the conjugate binding was challenged by competition experiments using an excess of uncoupled bradykinin (W3 M) and/or HOE140 M was the highest concentration of the ligands that still gave specific staining with the anti-ligand anti-M) for conjugate displacement.
bodies. Ligand conjugate staining of tissues from male or female rats did not reveal signifcant differences between the sexes (not shown).
Light Microscopy Immunocytochemistry. Immunostaining was pcrformed according to the peroxidase-anti-peroxidase (PAP) method of Stcmberger et al. (1970) . with modifications described earlier (Figueroa et al., 1984a (Figueroa et al., . 1988 Controls for the immunostaining procedure were prepared by omission of the fmt antibody and its replacement by non-immune rabbit serum or an unrelated anti-peptide antiserum (rabbit anti-vasoactive intestinal polypeptide; Amersham, h l e , UK) at the sane dilutions. Altemativcly, the pool mixture of anti-peptide antisera (AS276 to AS283) was pre-absorbed overnight at 4'C with an excess of the same peptides (100-200 Pglml) used for immunizations, and then centrifuged at 10,000 x g to remove the immune precipitates.
Topological RJationships Among B2 Receptor, T h e K;lllikrrin . and Kininogen. The topological relationships among tubules containing the kinin-forming enzyme tissue kallikrein, its substrate kininogen, and the kinin B2 receptor were analyzed on serial tissue sections, 6-7 pm thick, that were incubated with antibodies against rat urinary kallikrein (1:2000-1:5000) ), kininogens (50 pg/ml affhitypurified antibody MBK2) (Kaufinann et al., 1993) . or the B2 receptor (mixture of AS276 to AS283, 1:lOOO).
Immunoelazron Microscopy. Renal tissue slices were fixed in periodate-lysine-paraformaldehyde for 4 hr at RT as already described. Sections 40 pm thick were made in a cryostat or in a vibratome, washed with Trissaline buffer (see above), and incubated with the anti-peptide antibody AS 276 or AS 282 (1:2OO each) overnight at 4°C under constant agitation. After washing the sections were immunostained following the PAP method (Figueroa et al., 19&la, b) or were directly incubated with 10-nm gold-labeled anti-rabbit immunoglobulins (ICN Biomedicals; Costa Mesa, CA). When the PAP method was used the reaction was enhanced with silver mcthenamine as previously described (Figueroa et al., 1984b Rodriguez et al., 1984 . Finally, the sections were embedded in an Epon-araldite mixture according to standard procedures. Controls with non-immune rabbit serum were performed simultaneously and incubation lasted for the same period of time.
Autoradiography. The bradykinin analogue TyP-bradykinin (Sigma) was radioactively labeled with [ '*'I]-iodine following our previously published protocol (Esuada et al., 1991) . Rat kidney samples were rapidly frozen in liquid nitrogen, sectioned (15-20 pm thick) in a cryostat at -30'C.
mounted on slides pre-coated with polylysine (Sigma), and stored at -20'C until use. Before incubation the slides were warmed to RT, dessicated under vacuum, and washed with Buffer A. Incubation was performed overnight at 4°C with 3-6 nM [1251]-Tyro-bradykinin dissolved in Buffer A and supplemented with ImM dithiothreitol, 140 pg/ml bacitracin. After incubation the sections were washed with cold Buffer A, air-dried rapidly, and exposed to KodaxX-Omat photographic film (Sigma) for 72 hr at -2O'C. Specificity of the binding was assessed by incubating the sections in the presence of 1 pM of unlabeled TyP-bradykinin. 
Results

Characterization of the Ligand Conjugates
To obtain specific probes for bradykinin B2-binding sites, we chemically coupled the agonist bradykinin or the antagonist HOE140 to BSA and probed for the accessibility of the conjugated ligands by MAbs MBK3 (anti-bradykinin) and MHOl (anti-HOE140), employing indirect ELISA (Figure 2) . A strong reaction was observed for the homologous combination, i.e., bradykinin conjugate and MBK3, and a weak reaction for the free peptide, but no response was observed with the heterologous combination, i.e., MBK3 and HOE140 conjugate or free HOE140 peptide (Figure 2, left) , and vice versa r (Figure 2, right) . Furthermore, the carrier protein BSA alone was not recognized by any of the antibodies. Hence, the BSAbound ligands retain their antigenicity for their corresponding antibodies.
To evaluate the receptor-binding capacity of the conjugated ligands, we performed competition binding experiments in which free bradykinin and the bradykinin-BSA conjugate (Figure 3 , left) or free HOE140 and the HOE140-BSA conjugate (Figure 3 , right) competed with [3H]-bradykinin for B2 receptor binding. The chemical coupling of the ligands to BSA significantly reduces their affinity for the receptor (IC50 10-100 nM) compared with the free ligands (IC50 0.1-1 nM). However, the binding affinity of the ligand conjugates still allows discrimination of nonspecific binding, e.g., by angiotensin-BSA or BSA alone (IC50 310,000 nM). Hence, the ligand conjugates in combination with their corresponding anti-ligand antibodies provide specific probes to explore bradykinin-binding sites.
Low-power Visualization of Bradykinin-binding Sites by HOE140-BSA and Bradykinin-BSA Conjugates
Conjugates of HOE140-BSA and bradykinin-BSA both bound specifically to sections of fixed renal tissue. The binding was strong and uniform in the outer stripe of the outer medulla and less intense in the inner stripe; weak staining was seen in the inner medulla and in the papilla (Figure 4a ). Some cortical nephron segments also displayed strong binding of HOE140-BSA. Optimal visualization of renal bradykinin-binding sites was achieved when the HOE14O-BSA conjugate was applied in a concentration range of 5-20 pg/ml and bradykinin-BSA at 2-5 pglml (data not shown).
The binding of each type of conjugate was effectively competed by a molar excess (1 mM) of uncoupled HOE140 or bradykinin (exemplified for HOE140-BSA in Figure 4b ). Similar results were obtained with the bradykinin-BSA conjugate (not shown).
Unlike the results obtained with the ligand conjugates, the renal bradykinin-binding sites were not visualized when various concentrations M-W7 M) of free HOE140 or bradykinin were applied followed by their respective anti-ligand antibody (exemplified for HOE140 in Figure 4c ). Only in the case of the highest bradykinin concentration (10-3 M) was a weak nonspecific staining observed (not shown). Furthermore, application of an kotypematched MAb (IgG1) did not reveal any specific staining ( Figure  4h ). We conclude that the ligand conjugate approach is specific, and its success may be due to the multivalent nature of the conjugates.
Low-power Visualization of B2 Receptors in Kidney Tissue Sections by Anti-peptide Antibodies
To further test the specificity of the ligand conjugate-anti-ligand approach and to analyze the relationship between bradykinin-HOE140-binding sites and authentic B2 receptors, we chose an im- A5Tm-h ure 4e) were used for these experiments. The results for the other individual antisera (AS276 to 281, AS283) directed to the putative extra-and intracellular domains of the B2 receptor were similar to those obtained for antiserum AS282 and for their mixture (Figures  4d and 4e) . Pre-absorption of the anti-peptide antisera mixture with an excess (100-200 pglml) of the peptides used for immunization completely quenched the specific immunostaining ( Figure  4f ). Likewise, application of an unrelated anti-peptide antiserum to vasoactive intestinal polypeptide, not present in the tubule cells, failed to produce specific staining (Figure 4g ). Three other antipeptide antisera to predicted loop structures did not react with the B2 receptor (not shown).
Autoradiographic detection with [ '251]-Tyr"-bradykinin ( Figure  4i ) revealed a receptor distribution that was largely congruent with the patterns of immunostaining obtained by the anti-peptide an-tibodies or by the ligand conjugate-anti-ligand approach. The consistency of results obtained by the three independent approaches strongly suggests that the bradykinin-binding sites revealed by the ligand conjugate-anti-ligand approach are likely to represent authentic B2 receptors, thus stressing the validity and specificity of the latter method. However, the quality and resolution provided by the immunocytochemistry with anti-peptide antibodies were superior to those provided by the other approaches.
Low power immunovisualization by the anti-peptide antibodies showed that B2 receptors are abundant in the outer stripe of the outer medulla, in the medullary rays, in the inner stripe of the outer medulla, and in the inner medulla (Figures 5a-5e ). Controls using an unrelated anti-peptide antiserum (Figure 5f) or an antiserum mixture pre-absorbed with the corresponding peptides (Figure 5g 
Cellular Localization of B2 Receptors ana' Topological Relationship witb Other Components of the Kdlikrein-Kinin System
Both immunovisualization of ligand conjugate binding and immunolabeling by anti-peptide antibodies were associated with the presence of B2 receptors in the straight portion of proximal tubules, the distal straight tubules (thick ascending limb of Henle), the connecting tubules, and the collecting ducts of the rat kidney ( Figures 5 and 6 ). We were unable to find specific staining of the glomerular structures, of the proximal convoluted tubules ( Figures  5 and 6) , and of the macula densa (not shown). Both binding and immunoreactivity were concentrated in the luminal plasma membrane and the basal portions of the cells present in these nephron segments (see Discussion). Bindinglimmunostaining was apparently present in the cytoplasm of the same cells. In addition, strong immunostaining was obserwd in smooth musde cells of renal blood vessels, 'especially of the cortical radial artery and of the afferent arterioles (Figure 6c) , consistent with the notion that kinins have renal vascular effefts. Controls with pre-absorbed antisera were negative (Figure 6e ). Our results demonstrate by anti-receptor antibodies and by anti-ligand antibodies that both proximal and distal tubules contain the B2 receptor, as does the media of arterioles; we did not c o n f i i these results using iodinated bradykinin analogues.
To investigate the topological relationship of the various components constituting the kinin system, we immunostained serial sections for the B2 receptor and tissue kallikrein (Figures 7a and  7c) or the B2 receptor and kininogen (Figures 7b and 7d) . The staining pattems demonstrate that the B2 receptor is present in kallikreincontaining cell layers of the connecting tubules and in kininogenbearing cell layers of the collecting ducts. Hence, the essential components of the kinin pathway, i.e., the releasing enzyme, the substrate, and the receptor, coexist in various segments of the nephron.
Immunoelectron Microscopic Visudization of tbe 82 Receptor by Anti-peptide Antibodies
Two anti-peptide antisera were used for ultrastructural localization of the B2 receptor. Antiserum AS282 directed to the putative third extracellular domain strongly reacted with the luminal membrane of the connecting tubules, of the collecting ducts, and of the thick ascending limb of Henle (Figure 8a ). Antiserum AS276 elicited to the putative second extracellular domain produced intense immunostaining that was prevalent in the basal infoldings of same nephron segments (Figure 8b ). Note that under the conditions used for subcellular immunolocalization of the B2 receptors, i.e., preembedding in the absence of a permeabilizing agent, no staining of the cytoplasm is seen.
Discussion
The renal kallikrein-kinin system is believed to play an important role in the regulation of electrolyte and water transport in the kidney (Carretero and Scicli, 1989) . Although the renal occurrence and localization of tissue kallikrein (Figueroa et al., 1984a (Figueroa et al., ,b,1988 Orstavik et al., 1976) and kininogen (Chao et al., 1988; Figueroa et al., 1988; Proud et al., 1981) are well documented, the identification, cellular localization, and subcellular distribution of the kinin B2 receptors in the kidney are unknown. Previous attempts to localize kinin-binding sites in the kidney by ligand autoradiography have focused on microdissected nephron segments from rabbit (Tomita and Pismo. 1984 ) and on kidney sections from guinea pig (Manning and Snyder, 1989) . The highest concentration of kininbinding sites was found in outer medullary collecting ducts.
Other workers have demonstrated binding of radiolabeled bradykinin to rat glomerular membranes (Bascands et al., 1989; Edmond et al., 1989) and to a cell line derived from rat medullary interstitial cells (Fredrick et al., 1985) . In this study we confirm the finding that kinin-binding sites are present in the collecting ducts. In addition, we have demonstrated the presence of kinin receptors in connecting tubules and in renal vascular tissue ( Figure  9 ). However, we have been unable to detect significant ligand binding or immunoreactivity in glomeruli and in medullary interstitial cells, where distinct effects of kinins have been reported (Fredrick et al., 1985; Bascands et al., 1989) . These discrepancies might reflect the detection limits of the applied procedures (immunostaining vs radioreceptor assay), the differential expression of the kinin receptors in the kidney (B1 vs B2), andlor differences in the access to or affinity of the ligand for the receptors (tissue sections vs membrane preparations).
Demonstration that B2 receptors are present both on the apical and basal side of the collecting duct cells is not unexpected. Previously, others have shown that the application of kinins on the apical face of cultured cortical collecting duct cells induces PGE2 release from these cells, whereas application to the basal side was without effect (Garcia-Perez and Smith, 1984) . By contrast, the kinins inhibit vasopressin-stimulated water permeability and sodium resorption on the basal but not on the apical side of microdissected collecting ducts (Tomita et al., 1985; Schuster et al., 1984) . Furthermore, the presence of kinin-binding sites has been demonstrated on both sides of renal papillary collecting tubule cells (Cuthbert et al., 1985) . These findings are consistent with the results of our immunolocalizations and point to the exposure of kinin receptors on both faces of the collecting duct cells. In addition, the cells of other tubule segments, i.e.. the distal straight and the connecting tubules, were clearly immunoreactive for the B2 receptor on both the basal and the luminal surface. Differences in the density of the staining (luminal vs basal cell membrane) produced by various anti-peptide antisera may reflect differences in the occupancy and/or 
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epitope accessibility of the B2 receptor on the apical site as opposed to the basal face. The significance of these differences remains unexplained. The presence and the functional significance of B2 receptors in nephron segments such as the proximal straight tubule and the distal straight tubule (thick ascending limb of Henle) remain to be assessed. Specifically, the question of whether kinin receptors located at these sites are involved in the establishment and maintenance of electrolyte balance is open to future research.
In recent years, the presence in the distal nephron of various components of the kinin-forming pathway such as kallikreins, kininogens, and kininases (Marchetti et al., 1987) has been well documented (for a recent review see Bhoola et al., 1992) . Furthermore, high concentrations of free kinin(s) were found in the terminal portions of the distal nephron (Scicli et al., 1978) , i.e., at a site where cells expressing tissue kallikrein and kininogen are juxtaposed (Figueroa et al., 1988) . Our present studies demonstrate that the same cells also display B2 receptors (Figure 9 ). Hence, the connecting tubules might represent prime targets for locally released kinins that could exert autocrine or paracrine effects on B2-bearing cells located at the same site.
In this study we have employed and evaluated an unusual method to localize peptide hormone receptor sites using (ant)agonistic ligands covalently coupled to a carrier protein, followed by antiligand antibodies. We refer to this method as the ligand conjugatelanti-ligand (LAL) approach. Coupling of the B2 ligands to a carrier protein is essential because application of "free" HOE140 or bradykinin produced weak, if any, specific staining at ligand concentrations <1 mM. This may indicate that the receptor interaction sites of the ligands overlap their antigenic epitopes, i.e.. once bound to the receptor the ligands are no longer accessible for their antibodies and vice versa. In addition, one would expect that the multivalent ligands bind to closely spaced receptors with higher affinities and slower off-rates than monovalent ligands. The utilization of BSA conjugates eliminates the problems associated with the antigenic recognition of the free ligands, and provides at the same time a sensitive and specific method that rests on the presence of at least two accessible ligands on the surface of the carrier protein. Our successful application of the LAL method using a rather poorly derivatized BSA conjugate (1.4 moles HOE140 per mole of BSA) which, on a mass-averaged basis, is reduced in affinity for the B2 receptor (see Figure 3 ) may seem surprising. Our success can be rationalized by considering that >30% of the conjugate molecules have two or more HOE140 ligands and that only these molecules will be detected by the LAL method. Furthermore, it is likely that multiply derivatized ligands have a higher affinity for surface receptors by multiple simultaneous interactions. Finally, the observed reduction in affinity, mass-averaged, still yields a high-affinity conjugate with an apparent IC50 of 20 nM; bradykinin's ICs0 is 2 nM (Figure 3 ). The LAL approach to localize receptor binding sites may complement the traditional strategies using radiolabeled ligands or antireceptor antibodies. The LAL strategy might be particularly usdul in settings where antibodies to a given receptor are not readily available but the corresponding agonistslantagonists are. In addition, probing for "functional" receptors with intact binding sites can be accomplished by the LAL technique, e.g., in cells transfected with a receptor DNA. One limitation may occur when the chemical coupling of the ligand interferes with its intrinsic affinity for the corresponding receptor. Because the LAL method rests on the preservation of the ligand-binding site of the target receptor, the fixation and processing conditions of the sample are critical to the success of this approach. Furthermore, the application of anti-ligand antibodies might yield false-positive results in settings where endogenous ligands and/or their precursors are present. This latter prob-lem is circumvented by the utilization of non-natural ligands such as HOE140. We envisage that the LAL approach may be applicable to non-peptide ligands such as biogenic amines and to the exploration of non-receptor binding proteins, thus offering the potential of a general method for visualization and quantitation of binding sites.
